Alphyn Biologics Amplifies Innovation with New Patent
Patent covers active pharmaceutical ingredient ensuring long-term protection.
Alphyn Biologics, a clinical-stage dermatology company committed to developing innovative Multi-Target Therapeutics, has made a notable advancement. The United States Patent and Trademark Office (USPTO) has awarded Alphyn a patent for the active pharmaceutical ingredient (API) in its leading candidate aimed at treating atopic dermatitis (AD). This strengthens its growing research and development efforts in dermatological therapies.
CEO Neal Koller expressed enthusiasm over this achievement, stating, "This is a significant milestone for Alphyn. With our existing patent protecting Zabalafin Hydrogel, we now have extensive protection for our products’ composition and the methods for making and using them." This new patent not only enhances the company's intellectual property but also emphasizes its commitment to innovative solutions in dermatological care.
The patent obtained covers the topical application of Alphyn's drug raw material specifically targeting the treatment of atopic dermatitis, extending protection for a considerable duration until 2041. Furthermore, it complements their existing patent for Zabalafin Hydrogel, which carries a protection term until 2043. Upon receiving FDA approval for the AD drug, both patents will be eligible for listing in the FDA's Orange Book, providing added regulatory benefits.
Alphyn's patent portfolio is expanding rapidly, covering its various therapeutic agents and its unique Multi-Target Therapeutic Platform, with numerous applications already filed across different global jurisdictions. The company has also recently received a Notice of Allowance on a crucial patent for Zabalafin Hydrogel from the European Patent Office, demonstrating its global ambition.
About Alphyn Biologics
Alphyn Biologics, Inc. is dedicated to the development of first-in-class Multi-Target Therapeutics for widely prevalent and severe skin conditions, leveraging its innovative Zabalafin Platform. Their flagship product, Zabalafin Hydrogel, is already showing promising efficacy and safety results from Phase 2a clinical trials, positioning it as a potential first-line treatment for atopic dermatitis.
The Zabalafin Hydrogel formulation is distinctive for its ability to address the multifaceted challenges posed by AD, targeting not only the intense itching, but also the bacterial aspect and the immune-inflammatory response associated with this common skin condition. This holistic approach aims to provide a worry-free, long-term treatment option.
Alphyn's Zabalafin Platform features multiple bioactive compounds, unveiling a variety of mechanisms designed to ensure effective outcomes, boosting the pipeline for dermatological therapies while emphasizing safety and tolerability for patients. Since commencing operations in 2020, Alphyn has successfully built a solid operational base in Annapolis, Maryland, and Cincinnati, Ohio, along with wholly-owned subsidiaries in Australia and Austria, raising around $21 million to drive its research and development.
The company’s focus on details and innovative strategies indicates its readiness to navigate the complex regulatory landscape while offering compelling solutions for patients struggling with skin diseases.
Frequently Asked Questions
What recent patent did Alphyn Biologics receive?
Alphyn Biologics received a new U.S. patent covering the active pharmaceutical ingredient for its lead candidate targeting atopic dermatitis, ensuring protection until 2041.
What is the significance of the Zabalafin Hydrogel?
Zabalafin Hydrogel is a unique topical treatment for atopic dermatitis, directly addressing its symptoms and underlying causes, potentially revolutionizing AD care.
How does Alphyn Biologics protect its innovations?
Alphyn has built a robust patent portfolio, including patents for both its API and Zabalafin Hydrogel, providing extensive IP protection across multiple jurisdictions.
Where is Alphyn Biologics based?
Alphyn Biologics has operational bases in Annapolis, Maryland, and Cincinnati, Ohio, with additional subsidiaries in Australia and Austria.
How much funding has Alphyn Biologics raised?
Since its inception in 2020, Alphyn Biologics has raised approximately $21 million to support its research and development efforts.
